Drosophila-generated CTL

NCT01271907 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Study was terminated due to withdrawal of CRADA partner.

Conditions

Metastatic Cutaneous Melanoma

Interventions

DRUG: fludarabine
DRUG: cyclophosphamide
DRUG: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)